Oppenheimer Starts Immunovant (IMVT) at Outperform, 'expect the execution to unlock considerable value'
Tweet Send to a Friend
(Updated - March 27, 2024 4:04 PM EDT)
Oppenheimer analyst Leland Gershell initiates coverage on Immunovant (NASDAQ: IMVT) with ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Oppenheimer analyst Leland Gershell initiates coverage on Immunovant (NASDAQ: IMVT) with ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
